Lackland D.T.,Weba M.A. “ .2015 .2015 global burden of cardiovascular disease and stroke: hypertension at the core. The Canadian Journal of Cardiology, 01(2015) : 569-571.
Carretero O.A.,Oparil S. . .Essential hypertension. Part I: definition and etiology. ” Circulation, 101(2000) : 329-335.
Poulter N.R. .2015 .. Hypertension.” The Lancet, 6736(14) : 61468-9.
Halade G.V. .2013 .Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. ” Pharmacology and Therapeutics, 03 : 32-40.
Newby A.C. .2009 .Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. ” Thrombosis and Haemostasis, 101 : 1006-1011.
Williams B. . .Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. ” Journal of Human Hypertension, 1001683(2004) : 139-185.
Meng L. . .Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. ” Journal of Hypertension, 30(2012) : 842-851.
Tsounis D. . .Inflammation markers in essential hypertension. ” Medicinal Chemistry, 10(2014) : 672-681.
Turchetti V. .1999 .Evaluation of hemorheological parameters and red cell morphology in hypertension. ” Clinical Hemorheology and Microcirculation, 21 : 285-289.
Rampling M.W. .1999 .Haemorheological disturbances in hypertension: the influence of diabetes and smoking. ” Clinical Hemorheology and Microcirculation, 21 : 183-187.
Yaghoubi A. .2013 .Role of platelet parameters and haematological indices in myocardial infarction and unstable angina. ” Journal of the Pakistan Medical Association, 63 : 1133-1137.
Kumar N.L. . .Study of lipid profile, serum magnesium and blood glucose in hypertension. ” Biology and Medicine, 2(2010) : 6-16.
Saha M.S. .2006 .Serum lipid profile of hypertensive patients in the northern region of Bangladesh. ” Journal of BioScience, 14 : 93-98.
Ferretti G. .2017 .Impact of statin therapy on plasma MMP3, MMP-9, and TIMP-1 concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. ” Angiology, 68(10) : 850-862.
Raffetto J.D.,Khalil R.A. .2008 .Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. ” Biochemical Pharmacology, 75 : 346-359.
Tan J. .2007 .Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. ” Hypertension Research, 30 : 959-963.
Dollery C.M. .1995 .Matrix metalloproteases and cardiovascular disease. ” Circulation Research, 77 : 863-868.
Fang H. .2014 .Molecular mechanisms associated with angiotensin-converting enzyme-inhibitory peptide activity on vascular extracellular matrix remodeling. ” Cardiology, 127 : 247-255.
Guo Y.S. .2015 .Impact of losartan and angiotensin II on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells. ” Molecular Medicine Reports, 11 : 1587-1594.
Ferroni P. .2003 .Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. ” Journal of Investigative Medicine, 51 : 295-300.
Panimathi R. .2022 .Impact of COVID-19 on renal function: a multivariate analysis of biochemical and immunological markers in patients. ” Cureus, 14(2) : .
Vasanthii R. .2022 .Prevalence of hs-CRP among Indians with hypertension. ” Bioinformation, 18(10) : 1041.
Chitrasivasankari G. .2022 .Lipid and renal profile in assessing the severity of alcoholic liver disease. ” Bioinformation, 18(10) : 1036.